** Shares of ophthalmic therapies developer Cloudbreak Pharma Inc 2592.HK jump 13.5% to HK$8.24, highest level since July 3, and on course for sixth straight session of gains

** Stock on track to end the month up 71.1%, the biggest monthly gain since debut in Hong Kong on July 3

** Company says Japan Patent Office and European Patent Office have granted patents to its core product CBT-009 for treatment of juvenile myopia in children and adolescents aged 5 to 19 years

** Success of the patent applications will enhance CBT-009's global reach and facilitate its collaboration with pharma corporations in establishing licensing arrangements for the manufacture, distribution of CBT-009 in Japan and Europe

** Since their July debut, Cloudbreak shares down 18.8% so far from the offer price HK$10.10

** YTD, Hong Kong's healthcare index .HSCIH up 73.8%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))